In an attempt to strengthen its cancer immunotherapy pipeline, Roche has entered into a definitive merger agreement to acquire Good Therapeutics for an upfront payment of US$250 M as well as further potential milestone payments. With the takeover, Roche gains access to Good Therapeutics’ conditionally active, PD-1-regulated IL-2 programme as well as its platform technology to develop further PD1-Il2 agonist therapies. Once complete, Good Therapeutics’ remaining assets will be spun off into a new company, called Bonum Therapeutics.